Earlier this month, Merck & Co. confirmed that its PD-1 inhibitor Keytruda has demonstrated superiority versus chemotherapy (the current standard of care) in first-line non-small-cell lung cancer patients with regard to both progression-free survival and overall survival.
With first-line NSCLC viewed as a key market for the PD-(L)1 inhibitor class – both as monotherapies and potentially when used in combination with chemotherapy and other checkpoint inhibitors – FirstWord is interviewing a prominent oncology key opinion leader on Monday (June 27) to gauge his view on the how the treatment paradigm will likely evolve.
Ask the expert! What do you want to know?
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the biomedical potential of CRISPR/Cas9-based gene editing.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.